Media ReleasesRadiopharm Theranostics

View All Radiopharm Theranostics News

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report


* Signed Letter of Intent (LOI) with GenesisCare to support Radiopharm’s first Phase 1 trial in Australia
* Entered supply agreement with TerraPower for access to Actinium-225, which will be utilized in drug trials involving targeted alpha therapy in multiple disease areas
* Signed licensing agreement with University of California Los Angeles (UCLA) Technology Development Group (UCLA-TDG) to license UCLA’s promising LRRC15 antibody “DUNP19”
* Acquired patents to three assets to target diagnosis and treatment of a range of solid tumours
* Acceleration in number of patients recruited for AVβ6-Integrin compassionate use
* Hester Larkin appointed as Non-Executive Director on Radiopharm’s Board
* Continued build out of management team

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 31 March 2022. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.